Vous êtes sur la page 1sur 8

Case Against Janssen Pharmaceutica

©2018 Dr Romesh Senewiratne-Alagaratnam

Over the past twenty two years I have been injected, against my will, with 3
different drugs manufactured and promoted by the Belgian drug company
Janssen Pharmaceutica. These injections were painful and unnecessary. Rather
than improving my health, they caused considerable pain and suffering as well
as the development of ‘side-effects’ also known as ‘adverse effects’. These
have included Parkinsonism, weight gain, reduced creativity, anhedonia (lack
of pleasure), sterility and loss of libido, hypersalivation and ‘drooling’,
akathesia (physical restlessness) and difficulty in speaking. They have also put
me at risk of longer term illness and early death.

I am claiming AU$200,000,000.00 in compensation from Janssen

Pharmaceutica. The money will be spent on continued expansion of the
Holistic University Network.

Janssen Pharmaceutica
From Wikipedia, the free encyclopedia

Jump to navigationJump to search

Janssen Pharmaceutica

Industry Pharmaceutical

Founded 1953

Headquarters Beerse, Belgium

Parent Johnson & Johnson

Website www.janssenpharmaceuticalsinc.com
Janssen Pharmaceutica is a pharmaceutical company headquartered in Beerse, Belgium. It
was founded in 1953 by Paul Janssen.
In 1961, Janssen Pharmaceutica was purchased by New Jersey-based American
corporation Johnson & Johnson, and became part of Johnson & Johnson Pharmaceutical
Research and Development (J&J PRD), now renamed to Janssen Research and Development
(JRD), which conducts research and development activities related to a wide range of human
medical disorders, including mental illness, neurological
disorders, anaesthesia and analgesia, gastrointestinal disorders, fungal
infection, HIV/AIDS, allergies and cancer. Janssen and Ortho-McNeil Pharmaceutical have been
placed in the Ortho-McNeil-Janssen group within Johnson & Johnson.


 1History
o 1.1Drugs developed
o 1.2In China

 2Controversies

 3See also

 4References

 5Sources

 6External links

The early roots of what would become Janssen Pharmaceutica date back to 1933. In
1933, Constant Janssen, the father of Paul Janssen, acquired the right to distribute the
pharmaceutical products of Richter, a Hungarian pharmaceutical company, for Belgium,
the Netherlands and Belgian Congo. On 23 October 1934, he founded the N.V. Produkten
Richter in Turnhout. In 1937, Constant Janssen acquired an old factory building in
the Statiestraat 78 in Turnhout for his growing company, which he expanded during World War
II into a four-storey building. Still a student, Paul Janssen assisted in the development
of paracetamol (USP: acetaminophen, often referred to generically under the trademark Tylenol)
under the name Perdolan, which would later become well-known . After the war, the name for the
company products was changed to Eupharma, although the company name Richter would
remain until 1956. [1]

Paul Janssen founded his own research laboratory in 1953 on the third floor of the building in
the Statiestraat, still within the Richter-Eurpharma company of his father. In 1955, he and his
team developed their first drug: Neomeritine (ambucetamide), an antispasmodic found to be
particularly effective for the relief of menstrual pain. On 5 April 1956, the name of the company
was changed to NV Laboratoria Pharmaceutica C. Janssen (named after Constant Janssen). On
27 April 1957, the company opened a new research facility in Beerse, but the move to Beerse
would not be completed until 1971-1972. On 2 May 1958, the research department in Beerse
became a separate legal entity, the N.V. Research Laboratorium C. Janssen.
On 24 October 1961, the company was acquired by the American corporation Johnson &
Johnson. The negotiations with Johnson & Johnson were led by Frans Van den Bergh, head of
the Board of Directors. On 10 February 1964, the name was changed to Janssen Pharmaceutica
N.V. and the seat of the company in Turnhout was also transferred to Beerse. The company was
led by Paul Janssen, Bob Stouthuysen and Frans Van Den Bergh. When, in 1971-1972 the
pharmaceutical production also moved to Beerse, the move from Turnhout was completed.
Between 1990 and 2004, Janssen Pharmaceutica expanded worldwide, and the company grew
in size to about 28000 employees worldwide.
From the beginning, Janssen Pharmaceutica emphasized as its core activity research for the
development of new drugs. The research department which was established in Beerse in 1957,
developed into a large research campus. In 1987, the Janssen Research Foundation (JRF) was
founded which performs research into new drugs at Beerse and in other laboratories around the
globe. Janssen Pharmaceutica became the Flemish company with the largest budget for
research and development. Beside the headquarters in Beerse with its research departments,
pharmaceutical production and the administrative departments, Janssen Pharmaceutica in
Belgium still has offices in Berchem (Janssen-Cilag), a chemical factory in Geel, and Janssen
Biotech in Olen.
The Chemical Production plant in Geel makes the active ingredients for the company’s
medicines. In 1975, the first plant of a new chemical factory Plant I was established in
Geel, Plant II was opened in 1977, Plant III' in 1984, and Plant IV in 1995. In 1999 the remaining
chemical production in Beerse was transferred to Geel. About 80% of its active components are
manufactured here. The site in Geel also manufactures about two-thirds of the worldwide
chemical production of the pharmaceutical sector of Johnson & Johnson. In 1995, the Center for
Molecular Design (CMD) was founded by Paul Janssen and Paul Lewi.
In 1999, clinical research and non-clinical development become a global organization within
Johnson & Johnson. In 2001, part of the research activities was transferred to the United States
with the reorganization of research activities in the Johnson & Johnson Pharmaceutical Research
Development (JJPRD) organization. The research activities of the Janssen Research
Foundation (JRF) and the R.W. Johnson Pharmaceutical Research Institute (PRI) (United States)
were merged into the new global research organization. A new building for pharmaceutical
development was completed in Beerse in 2001. In 2002, a new logistics and informatics centre
was opened at a new site, Beerse 2. In 2003 two new research buildings were constructed,
the Discovery Research Center (DRC), and the Drug Safety Evaluation Center (DSEC). On 27
October 2004, the Paul Janssen Research Center, for discovery research, was inaugurated.
In March 2015, Janssen licensed tipifarnib (a farnesyl transferase inhibitor) to Kura
Oncology who will assume sole responsibility for developing and commercialising the anti-cancer
drug. Later in the same month the company announced that Galapagos Pharma and regained

the rights to the anti-inflammatory drug candidate GLPG1690 as well as two other compounds
including GLPG1205 (a first-in-class inhibitor of GPR84). [3]

In May 2016, the company launched a collaboration MacroGenics and their preclinical cancer
treatment, MGD015. The deal could net MacroGenics more than $740 million. [4]

In September 2017 it was announced that Janssen teamed up with the Biomedical Advanced
Research and Development Authority (BARDA), a unit of the U.S. Department of Health and
Human Services, to create pandemic flu vaccines. BARDA is giving Janssen $43 million in the
first year and $273 million over five years for the contract. One of the projects in the contract is
the development of a universal flu vaccine. The intent of the vaccine would be to protect people
against all or most flu strains.

Drugs developed[edit]
Risperdal tablets

R-code Name Brand name Synthetized Marketed

R5 ambucetamide Neomeritine 1953 1955

R79 isopropamide iodide Priamide-Janssen 1954 1955

R253 diisopromine Bilagol 1955 1956

R516 cinnarizine Stugeron 1955 1958

R875 dextromoramide Palfium 1955 1957

R1132 diphenoxylate Reasec 1956 1960

R1625 haloperidol Haldol 1958 1959

R2498 trifluperidol Triperidol 1959 1961

R3345 pipamperone Dipiperon 1960 1961

R3365 piritramide Dipidolor 1960 1967

R4263 fentanyl[6][7] Sublimaze 1960 1963

R-code Name Brand name Synthetized Marketed

R4584 benperidol Frenactyl 1961 1965

R4749 droperidol[8] Dehydrobenzperidol 1961 1963

R4845 bezitramide Burgodin 1961 1971

R6218 fluspirilene Imap 1963 1971

R6238 pimozide Orap 1963 1970

R7904 lidoflazine Clinium 1964 1969

R11333 bromperidol Impromen 1966 1981

R12564 levamisole Ergamisol 1966 1969

R13672 haloperidol decanoate Haldol decanoas 1967 1981

R14889 miconazole nitrate Daktarin 1967 1971

R14950 flunarizine Sibelium 1967 1977

R15889 lorcainide Remivox 1968 1983

R16341 penfluridol Semap 1968 1973

R16470 dexetimide Tremblex 1968 1972

R16659 etomidate[9][10] Hypnomidate 1964 1977

R17635 mebendazole Vermox 1968 1972

R18553 loperamide Imodium 1969 1973

R33800 sufentanil[11] Sufenta 1974 1979

R-code Name Brand name Synthetized Marketed

R33812 domperidone Motilium 1974 1978

R35443 oxatomide Tinset 1975 1981

R39209 alfentanil[12][13] Rapifen 1976 1983

R33799 carfentanil[14] Wildnil 1976 1980?

R41400 ketoconazole Nizoral 1976 1981

R43512 astemizole Hismanal 1977 1983

R46541 bromperidol decanoate Impromen decanoas 1978 1984

R49945 ketanserin tartrate Sufrexal 1980 1987

R50547 levocabastine Livostin 1979 1989

R51211 itraconazole Sporanox 1980 1986

R51619 cisapride Prepulsid 1980 1989

R64766 risperidone Risperdal 1984 1993

R207910 bedaquiline Sirturo 2004 2012

Janssen Pharmaceutica has developed and brought to the market about 70 new active
substances (NCE), of which the most well-known are (name may differ):

 Imodium (against diarrhoea. Active substance: loperamide)

 Motilium (against flatulence — and bowel impairments. Active substance: domperidone)
 Reminyl (against Alzheimer's disease (dementia). Active substance: galantamine)
 Daktarin (against fungal infections. Active substance: miconazole)
 Nizoral (against dandruff, Active substance: ketoconazole)
 Duragesic (fentanyl patch for pain suppression. Active substance: fentanyl)
 Vermox (against worms. Active substance: mebendazole)
 Risperdal (antipsychotic, against mental illness such as schizophrenia. Active
substance: risperidone)
Eight Janssen drugs have been included on the WHO Model List of Essential Medicines:
 Imodium (loperamide)
 Haldol (haloperidol)
 Ergamisol (levamisole)
 Daktarin (miconazole)
 Vermox (mebendazole)
 Nizoral (ketoconazole) (Removed in 2005)
 Risperdal (risperidone)
 Sirturo (bedaquiline) - an diarylquinoline anti-tuberculosis drug, discovered by Koen
Andries and his team, which promises a shorter and simpler treatment for multi-drug-
resistant tuberculosis (MDR-TB).
In China[edit]
This section does not cite any sources. Please help improve this section by adding citations to reliable sources. Unsourced material may be challenged
and removed. (October 2010) (Learn how and when to remove this template message)


Janssen Pharmaceutica was the first Western pharmaceutical company to set up a

pharmaceutical factory in the People's Republic of China.
In 1976, Paul Janssen met Ma Haide (born George Shafik Hatem), a Lebanese-American doctor
who had started working in China in 1933. After three days of meetings, the two agreed to bring
a modernized pharmaceutical business to China. When Chairman Deng Xiaoping opened China
to the West in 1978, Janssen Pharmaceutica sent Paul Appermont and Joos Horsten to set up
the project.
In 1983, Janssen signed a cooperation contract to modernize production in an old chemical
factory in the city of Hanzhong, in Shaanxi province. This factory would soon produce the active
compound of some Janssen products, such as mebendazole. In 1985, now operating as Xian-
Janssen Pharmaceuticals, a new large factory was opened in the city of Xi'an, also in Shaanxi

Juries in several US states have found that Janssen Pharmaceutical and its parent company
Johnson & Johnson deceptively promoted the antipsychotic drug Risperdal (risperidone). By
2012, four states had been awarded damages, including Louisiana ($258 million in 2010), South
Carolina ($327 million in 2011), Texas ($158 million in 2012), and most notably Arkansas ($1.2
billion in 2012) - whose Attorney General stated: “These two companies put profits before people,
and they are rightfully being held responsible for their actions". [15]

In a related issue, Risperdal sales practices resulted in a 2012 provisional settlement totaling
$2.3 billion. The United States Department of Justice began investigating Risperdal sales

practices in 2004, and in 2010 joined a whistleblowers suit alleging bribes paid to Omnicare, the
largest company supplying pharmaceutical drugs to nursing homes. The allegations include [17][18]

that Johnson & Johnson and Janssen were warned by the U.S. Food and Drug
Administration (FDA) not to promote Risperdal as effective and safe for elderly patients when in
fact it is associated with early death, but they did so; and that they in fact bribed Omnicare
pharmacists tens of millions of dollars to promote the drug to care home physicians for this
unapproved use. A settlement was provisionally agreed with Johnson & Johnson of around $2.2
billion for this and related allegations, with Omnicare having already settled for around $100
million. Former head of sales and president of Janssen, Alex Gorsky, who the Dept of Justice

say “was actively involved” in the fraud, nevertheless become the new CEO of Johnson &
Johnson in 2012.[19]